TY  - JOUR
T1  - The effect of Calcium channel blocker in the Betamethasone-induced Glaucoma model in rabbits
A1  - Waleed K. Abdulsahib
A1  - Sattar J. Abood
JF  - Journal of Advanced Pharmacy Education and Research
JO  - J Adv Pharm Educ Res
SN  - 2249-3379
Y1  - 2021
VL  - 11
IS  - 1
DO  - 10.51847/2d3w8vfSVt
SP  - 135
EP  - 140
N2  - To Evaluate the Ocular-hypotensive Effect of Levamlodipine in the Betamethasone- induced Glaucoma Model in the Rabbits. Ocular-hypertension was made by weekly subconjunctival injection of Celestone Chronodose® for four weeks in the right eye and the left eye was left as a control. The animals were divided into three groups, twice-daily eye drops of Levamlodipine 0.25%, Levamlodipine 0.5 %, and Timolol maleate 0.5% were administered to groups 1, 2, and 3 respectively (n = 6 for each group) for 12 days after week 4 of induction. All left eyes (control) administered sterile distilled water (DW) twice daily.

The subconjunctival administration of corticosteroid weekly after four weeks creates a significant (p˂ 0.001) increment in IOP in right eyes in groups 1, 2, and 3. Levamlodipine 0.25% shows a significant decrease in IOP after 3 days (p˂0.001), reaching 23.31±0.56 mmHg. Group 2 that administered 0.5% Levamlodipine, IOP significantly reduced (p˂0.001) (from 23.93±0.61 mmHg to 20.93±0.76 mmHg). Levamlodipine 0.5% produced a significant (p˂ 0.001) drop in the IOP when compared to Levamlodipine 0.25% and Timolol 0.5 in days 6, 9 and 12. During the study period, no systemic adverse events were observed in the left and right eyes of all groups. Levamlodipine has a promising beneficial effect in reducing intraocular pressure in the chronic model of glaucoma‎.
UR  - https://japer.in/article/the-effect-of-calcium-channel-blocker-in-the-betamethasone-induced-glaucoma-model-in-rabbits
ER  -